GR20020100189A - Prostate specific membane antigen prodrugs - Google Patents
Prostate specific membane antigen prodrugsInfo
- Publication number
- GR20020100189A GR20020100189A GR20020100189A GR2002100189A GR20020100189A GR 20020100189 A GR20020100189 A GR 20020100189A GR 20020100189 A GR20020100189 A GR 20020100189A GR 2002100189 A GR2002100189 A GR 2002100189A GR 20020100189 A GR20020100189 A GR 20020100189A
- Authority
- GR
- Greece
- Prior art keywords
- therapeutic agent
- psma
- prostate specific
- antigen
- membane
- Prior art date
Links
- 239000000651 prodrug Substances 0.000 title abstract 3
- 229940002612 prodrug Drugs 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 210000002307 prostate Anatomy 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 6
- 229940124597 therapeutic agent Drugs 0.000 abstract 6
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 abstract 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 abstract 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 1
- 108010020346 Polyglutamic Acid Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- 235000013922 glutamic acid Nutrition 0.000 abstract 1
- 239000004220 glutamic acid Substances 0.000 abstract 1
- 230000002797 proteolythic effect Effects 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
his invention provides targeted activation of biologically active compounds. A prodrug compises a therapeutic agent and a glutamic acid, which is linked to the therapeutic agents via a carboxyl grup, forming an amide bond. This linkage is specifically cleavable by proteolytic prostate specific membrane antigen (PSMA) activity or PSMA-like domains to release the therapeutic agent. The released therapeutic agent is more active than the prodrug and is only formed where PSMA or PSMA-like domains are present. In some embodiments of this invention the therapeutic agent is linked to polyglutamate.In other embodiments a linker may be present between the glutamate and the therapeutic agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20020100189A GR20020100189A (en) | 2002-04-17 | 2002-04-17 | Prostate specific membane antigen prodrugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20020100189A GR20020100189A (en) | 2002-04-17 | 2002-04-17 | Prostate specific membane antigen prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GR20020100189A true GR20020100189A (en) | 2003-12-22 |
Family
ID=29764771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GR20020100189A GR20020100189A (en) | 2002-04-17 | 2002-04-17 | Prostate specific membane antigen prodrugs |
Country Status (1)
| Country | Link |
|---|---|
| GR (1) | GR20020100189A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996026272A1 (en) * | 1995-02-24 | 1996-08-29 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
| WO2000064486A2 (en) * | 1999-04-28 | 2000-11-02 | Vectramed, Inc. | Enzymatically activated polymeric drug conjugates |
| WO2002043773A2 (en) * | 2000-12-01 | 2002-06-06 | The Johns Hopkins University | Tissue specific prodrugs |
-
2002
- 2002-04-17 GR GR20020100189A patent/GR20020100189A/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996026272A1 (en) * | 1995-02-24 | 1996-08-29 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
| WO2000064486A2 (en) * | 1999-04-28 | 2000-11-02 | Vectramed, Inc. | Enzymatically activated polymeric drug conjugates |
| WO2002043773A2 (en) * | 2000-12-01 | 2002-06-06 | The Johns Hopkins University | Tissue specific prodrugs |
Non-Patent Citations (3)
| Title |
|---|
| HESTON W D W ET AL: "Polygammaglutamated folate analogs as pro-drugs for prostate cancer.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 39, March 1998 (1998-03-01), 89th Annual Meeting of the American Association for Cancer Research;New Orleans, Louisiana, USA; March 28-April 1, 1998, March, 1998, pages 432, XP002223497, ISSN: 0197-016X * |
| HESTON W D: "Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase.", UROLOGY, (1997 MAR) 49 (3A SUPPL) 104-12., XP000906932 * |
| HESTON, WARREN D. W. ET AL: "Prostate-specific membrane antigen, a unique folate hydrolase: potential target for prodrug therapy", MOLECULAR UROLOGY (1997), 1(2/3), 215-219, XP008011260 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1178958E (en) | N-CYANOMETILAMIDES AS PROTEASE INHIBITORS | |
| ATE347378T1 (en) | CONJUGATES FOR THE TREATMENT OF INFLAMMATORY DISEASES AND ASSOCIATED TISSUE DAMAGE | |
| ATE507845T1 (en) | POLYACETAL DRUG CONJUGATES AS A RELEASE SYSTEM | |
| WO2007038209A3 (en) | Fused tetracyclic mglur1 antagonists as therapeutic agents | |
| WO2004021861A3 (en) | Targeted release | |
| EP1632477A4 (en) | Benzamide derivative or salt thereof | |
| SE0102327D0 (en) | A novel engineered superantigen for human therapy | |
| CO5611160A2 (en) | CONJUGATES OF THERAPEUTIC OR CYTOTOXIC AGENTS AND BIOLOGICALLY ACTIVE PEPTIDES | |
| NO20054185L (en) | Methods of radiofluorination of biologically active vectors | |
| ATE426414T1 (en) | VITAMIN-MITOMYCIN CONJUGATES | |
| EP1404356A4 (en) | COMPOUNDS FOR ACTIVE PROMEDICAMENTS CD10 | |
| WO2003104425A3 (en) | Novel stable anti-cd22 antibodies | |
| MX2007003907A (en) | Therapeutic agents with decreased toxicity. | |
| DE602006014821D1 (en) | EX-VIVO GENERATION PROCEDURE | |
| SG149872A1 (en) | Antagonists of the bradykinin b1 receptor | |
| MA30139B1 (en) | PREPARATION OF GAMMA-AMINOACIDS HAVING AFFINITY FOR THE PROTEIN ALPHA-2-DELTA | |
| DE602006019911D1 (en) | MGLUR1 ANTAGONISTS AS THERAPEUTIC ACTIVITIES | |
| EP1781277A4 (en) | COMBINED COMPOSITION | |
| WO2007005941A3 (en) | Liver targeted conjugates | |
| Mhaka et al. | A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer | |
| ATE425770T1 (en) | CONTRAST AGENTS | |
| GR20020100189A (en) | Prostate specific membane antigen prodrugs | |
| ITMI20022394A1 (en) | USE OF 3-SULPHATE TRIODOTHYRONIN AS A THYROIMIMETIC ACTIVITY AND RELATED PHARMACEUTICAL FORMULATIONS. | |
| BR0315055A (en) | Pyrimidin-4,6-dicarboxylic acid diacids for selective collagenase inhibition | |
| WO2005094265A3 (en) | Self assembling activation agents targeted using active drug release |